Hepatocellular Carcinoma Classification and Current Treatment
Annals of Radiology · 2022
DOI: 10.52338/aor.2022.3019 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Radiology, 2022. Verfasst von Robert Elliott.
Abstract (Originalsprache)
Hepatic cirrhosis is a risk factor for the development of the aggressive primary liver cancer known as hepatocellular carcinoma (HCC). The Hepatitis C virus, which causes cirrhosis, is becoming more common in the United States, which has led to an increase in HCC cases. When tumours are modest, curative treatment for HCC is indicated and may entail radiofrequency ablation, liver transplantation, or surgical resection. Transarterial chemoembolization and transarterial radioembolization are two locoregional treatments that can be utilised either as a primary therapy or as an adjuvant to surgical care. The initial monitoring of individuals at risk for HCC, the most recent recommendations for HCC diagnosis and staging, and a review of the best practises for HCC therapy will all be covered in this review article
Zitieren
APA
Elliott, R. (2022). Hepatocellular Carcinoma Classification and Current Treatment. Annals of Radiology. https://doi.org/10.52338/aor.2022.3019
Vancouver
Elliott R. Hepatocellular Carcinoma Classification and Current Treatment. Annals of Radiology. 2022. doi:10.52338/aor.2022.3019
BibTeX
@article{Elliott2022,
author = {Elliott, Robert},
title = {Hepatocellular Carcinoma Classification and Current Treatment},
journal = {Annals of Radiology},
year = {2022},
doi = {10.52338/aor.2022.3019}
}
EUVIMED